Half-Year 2022 Financial and Clinical Trials Update
ElecsysⓇ HCV DUO Immunoassay1
Early diagnosis of hepatitis C virus (HCV) enables optimal treatment
Roche
relative concentration
in blood
Diagnostic window period²
6-12 weeks
HCV RNA/
core antigen
anti-HCV
antibodies
#
02 4 6 8
10
12
24
weeks post-infection
Testing strategies relying on first-line HCV antibody testing may lead to
underdiagnoses in populations with ongoing transmission
•
.
•
58m people being chronically infected globally (80% unaware³)
and about 1.5m new infections per year
Hepatitis C leading cause for liver cancer and curative
treatments are available4
Shortening diagnostics window by up to 3 weeks compared to
HCV antibody test
Dual detection of antigen and antibody simplifies the HCV
testing/screening algorithm while complementing RNA testing
WHO elimination strategy aims to significantly reduce new
infections and deaths by 2030
RNA: ribonucleic acid WHO: World Health Organisation; 1 Available in CE market; 2 Glynn S.A. et al. (2005). Dynamics of viremia in early hepatitis C virus infection. Transfusion 45, 994-1002. https://doi.org/10.1111/j.1537-
2995.2005.04390.x; 3 Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016-2021: actions for impact. Geneva: World Health
Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/publications/i/item/9789240027077; 4 Fact Sheet. Viral Hepatitis and Liver Cancer. CDC; 2016.
https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/viral-hep-liver-cancer.pdf
44View entire presentation